De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Tonix Pharmaceuticals Holding Toekomstige groei
Future criteriumcontroles 2/6
Tonix Pharmaceuticals Holding is forecast to grow earnings and revenue by 33.8% and 51.5% per annum respectively while EPS is expected to grow by 128% per annum.
Belangrijke informatie
33.8%
Groei van de winst
128.0%
Groei van de winst per aandeel
Biotechs winstgroei | 28.6% |
Inkomstengroei | 51.5% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 09 Sep 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 41 | -63 | N/A | N/A | 2 |
12/31/2025 | 16 | -76 | N/A | N/A | 3 |
12/31/2024 | 9 | -80 | N/A | N/A | 1 |
6/30/2024 | 12 | -149 | -76 | -73 | N/A |
3/31/2024 | 10 | -99 | -91 | -87 | N/A |
12/31/2023 | 8 | -117 | -110 | -102 | N/A |
9/30/2023 | 4 | -123 | -114 | -102 | N/A |
6/30/2023 | N/A | -124 | -121 | -102 | N/A |
3/31/2023 | N/A | -123 | -132 | -100 | N/A |
12/31/2022 | N/A | -117 | -146 | -98 | N/A |
9/30/2022 | N/A | -112 | -167 | -98 | N/A |
6/30/2022 | N/A | -102 | -156 | -88 | N/A |
3/31/2022 | N/A | -98 | -141 | -86 | N/A |
12/31/2021 | N/A | -92 | -111 | -76 | N/A |
9/30/2021 | N/A | -80 | -81 | -67 | N/A |
6/30/2021 | N/A | -73 | -80 | -69 | N/A |
3/31/2021 | N/A | -64 | -69 | -60 | N/A |
12/31/2020 | N/A | -52 | -57 | -49 | N/A |
9/30/2020 | N/A | -46 | -45 | -41 | N/A |
6/30/2020 | N/A | -42 | -33 | -33 | N/A |
3/31/2020 | N/A | -34 | -27 | -27 | N/A |
12/31/2019 | N/A | -31 | -27 | -27 | N/A |
9/30/2019 | N/A | -31 | -27 | -27 | N/A |
6/30/2019 | N/A | -28 | -25 | -25 | N/A |
3/31/2019 | N/A | -29 | -26 | -26 | N/A |
12/31/2018 | N/A | -29 | -24 | -24 | N/A |
9/30/2018 | N/A | -24 | -22 | -22 | N/A |
6/30/2018 | N/A | -24 | -22 | -22 | N/A |
3/31/2018 | N/A | -23 | N/A | -21 | N/A |
12/31/2017 | N/A | -21 | N/A | -19 | N/A |
9/30/2017 | N/A | -23 | N/A | -20 | N/A |
6/30/2017 | N/A | -25 | N/A | -23 | N/A |
3/31/2017 | N/A | -30 | N/A | -27 | N/A |
12/31/2016 | N/A | -39 | N/A | -37 | N/A |
9/30/2016 | N/A | -45 | N/A | -44 | N/A |
6/30/2016 | N/A | -50 | N/A | -48 | N/A |
3/31/2016 | N/A | -52 | N/A | -49 | N/A |
12/31/2015 | N/A | -48 | N/A | -43 | N/A |
9/30/2015 | N/A | -44 | N/A | -39 | N/A |
6/30/2015 | N/A | -38 | N/A | -31 | N/A |
3/31/2015 | N/A | -32 | N/A | -28 | N/A |
12/31/2014 | N/A | -28 | N/A | -23 | N/A |
9/30/2014 | N/A | -22 | N/A | -18 | N/A |
6/30/2014 | N/A | -18 | N/A | -16 | N/A |
3/31/2014 | N/A | -14 | N/A | -11 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: TNXP is forecast to remain unprofitable over the next 3 years.
Winst versus markt: TNXP is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: TNXP is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: TNXP's revenue (51.5% per year) is forecast to grow faster than the US market (8.7% per year).
Hoge groei-inkomsten: TNXP's revenue (51.5% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if TNXP's Return on Equity is forecast to be high in 3 years time